

NOW AVAILABLE
40 mg/mL dosage

Real world experience. Free patient support. Go Glatopa®.

Glatopa 20 mg/mL (glatiramer acetate injection) is the #1 prescribed generic glatiramer acetate 20 mg/mL since launch in June 2015



~40% ~40% of total glatiramer acetate 20 mg/mL prescriptions are for Glatopa 20 mg/mL^{1,2*} (October 2017 to February 2018)



93% 93% of neurologists surveyed who prescribe Glatopa 20 mg/mL (glatiramer acetate injection) reported being satisfied with Glatopa overall^{3†}



97% 97% of patients surveyed reported being satisfied with their GlatopaCare experience^{4‡}

*Adapted from IMS NPA Monthly, Total Glatopa Prescriptions and Sandoz Inc., sales data for Kaiser and the VA.

†Independent market research. Neurologists were moderately or extremely satisfied based on a 1-10 scale where 10=extremely satisfied, with moderately satisfied scored as 4-7 and extremely satisfied scored as 8-10. Scores were gathered in an online survey of 44 respondents, July-September 2016.

‡Based on a survey conducted August 16-25, 2016, of 151 patients taking Glatopa 20 mg/mL and enrolled in GlatopaCare, using a scale where 1=not at all satisfied and 7=extremely satisfied; 146 patients, or 97%, provided a score of ≥3.

In addition to therapeutic equivalence, Glatopa offers your patients the quality and services you expect with a brand name

| | Glatopa® (glatiramer acetate injection) | Mylan (glatiramer acetate injection) |
|--|---|--|
| Therapeutically equivalent to Copaxone®⁵ (glatiramer acetate injection) | ✓ | ✓ |
| Device does not require a separate Rx⁶ | ✓ | ✗ |
| Manufactured in the USA^{7,8} | ✓ | ✗ |
| Real-world experience (nearly 3 years)^{1,9} | ✓ (20 mg/mL) | ✗ |
| Patient starter kit¹⁰ | ✓ | ✗ |

Copaxone is a registered trademark of Teva Pharmaceutical Industries Ltd.

Indication

Glatopa® (glatiramer acetate injection) is indicated for the treatment of patients with relapsing-forms of multiple sclerosis.

Important Safety Information

Glatopa® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.

Approximately 16% of glatiramer acetate injection 20 mg/mL patients vs 4% of those on placebo, and approximately 2% of glatiramer acetate injection 40 mg/mL patients vs none on placebo experienced a constellation of symptoms that may occur within minutes after injection and included at least 2 of the following: flushing, chest pain, palpitations, tachycardia, anxiety, dyspnea, throat constriction, and urticaria. These symptoms generally have their onset several months after the initiation of treatment, although they may occur earlier, and a given patient may experience 1 or several episodes of these symptoms. Typically, the symptoms were transient and self-limited and did not require treatment; however, there have been reports of patients with similar symptoms who received emergency medical care.

Transient chest pain was noted in 13% of glatiramer acetate injection 20 mg/mL patients vs 6% of placebo patients, and approximately 2% of glatiramer acetate injection 40 mg/mL patients vs 1% on placebo. While some episodes of chest pain occurred in the context of the immediate post-injection reaction described above, many did not. The temporal relationship of this chest pain to an injection was not always known. The pain was transient, often unassociated with other symptoms, and appeared to have no clinical sequelae. Some patients experienced more than 1 such episode, and episodes usually began at least 1 month after the initiation of treatment.

At injection sites, localized lipoatrophy and, rarely, injection site skin necrosis may occur. Lipoatrophy may occur at various times after treatment onset (sometimes after several months) and is thought to be permanent. There is no known therapy for lipoatrophy.

Please see additional Important Safety Information on back and enclosed full Prescribing Information.

Glatopa®
(glatiramer acetate injection)

The Glatopa® Starter Kit makes getting started with Glatopa easy

The Glatopa (glatiramer acetate injection) Starter Kit contains everything your patients need to start injecting daily:

- **Sharps Container:** Allows for safe and convenient disposal of used needles
- **Cooler Bag:** Keeps Glatopa cool while away from home
- **Glatopaject® Injection Demonstration Video:** Step-by-step patient guide for using the Glatopaject Injection Device
- **Lifestyle Manual:** A patient reference guide to starting Glatopa
- **Injection Preparation Mat:** Assists patients with injection preparation



Encourage your patients to enroll in GlatopaCare® today and receive a free Patient Starter Kit. Patients can enroll by calling **1.855.GLATOPA** (1.855.452.8672) or by visiting **glatopa.com/register**

*Glatopa Co-Pay Program Eligibility

The Glatopa Co-Pay Program provides up to \$9,000 in annual Co-Pay support for Glatopa prescriptions. This program is not health insurance. This program is for insured patients only; uninsured cash-paying patients are not eligible. Patients are not eligible if prescriptions are paid, in whole or in part, by any state or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DOD, or TriCare, or private indemnity, or HMO insurance plans that reimburse you for the entire cost of your prescription drugs, or where prohibited by law. Card may not be combined with any other rebate, coupon, or offer. Card has no cash value. Sandoz reserves the right to rescind, revoke, or amend this offer without further notice.

References: **1.** Data on file. IMS Health. Sandoz Inc. Princeton, NJ. February 2018. **2.** Data on file. Glatopa sales data. Sandoz Inc., Princeton, NJ. February 2018. **3.** Data on file. MS market research report. Sandoz Inc. Princeton, NJ. September 2016. **4.** Data on file. Rx Crossroads GlatopaCare Survey. Sandoz Inc. Princeton, NJ. August 2016. **5.** Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration website. <http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM071436.pdf>. Accessed May 18, 2018. **6.** Generic Glatiramer Acetate Mylan MS Advocate™ Patient Start Form. http://www.glatirameracetate.com/-/media/glatirameracetate/documents/msadvocatepatientenrollmentform20mgand40mg_update1. Accessed October 18, 2017. **7.** Glatiramer Acetate Injection 20 mg/mL [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; 2018. **8.** Glatiramer Acetate Injection 40 mg/mL [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; 2018. **9.** Sandoz announces US launch of Glatopa™, the first generic competitor to Copaxone® 20mg [press release]. Holzkirchen, Germany: Novartis Pharmaceuticals; June 19, 2015. **10.** Mylan MS Resources. <http://www.glatirameracetate.com/en/ms-resources#>. Accessed October 18, 2017.

Important Safety Information (cont'd)

Because glatiramer acetate can modify immune response, it may interfere with immune functions. For example, treatment with glatiramer acetate may interfere with recognition of foreign antigens in a way that would undermine the body's tumor surveillance and its defenses against infection. There is no evidence that glatiramer acetate does this, but there has not been a systematic evaluation of this risk.

The most common adverse reactions with glatiramer acetate injection 20 mg/mL vs placebo were injection site reactions (ISRs), such as erythema (43% vs 10%); vasodilatation (20% vs 5%); rash (19% vs 11%); dyspnea (14% vs 4%); and chest pain (13% vs 6%). The most common adverse reactions with glatiramer acetate injection 40 mg/mL vs placebo were ISRs, such as erythema (22% vs 2%).

ISRs were one of the most common adverse reactions leading to discontinuation of glatiramer acetate injection. ISRs, such as erythema, pain, pruritus, mass, edema, hypersensitivity, fibrosis, and atrophy, occurred at a higher rate with glatiramer acetate than placebo.

To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information on cover and back, and enclosed full Prescribing Information.